Randomized clinical trial to assess the benefit of adding trastuzumab to capecitabine and vinorelbine as second line treatment for HER2 positive breast cancer patients with locally advanced or metastatic disease, progressing to a previous therapy line with trastuzumab and taxanes.

Trial Profile

Randomized clinical trial to assess the benefit of adding trastuzumab to capecitabine and vinorelbine as second line treatment for HER2 positive breast cancer patients with locally advanced or metastatic disease, progressing to a previous therapy line with trastuzumab and taxanes.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 25 Oct 2011

At a glance

  • Drugs Capecitabine; Trastuzumab; Vinorelbine
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Oct 2011 Planned End Date changed from 1 Dec 2007 to 1 Jun 2009 as reported by ClinicalTrials.gov.
    • 25 Oct 2011 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
    • 25 Oct 2011 PEC (therapeutic area) has been removed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top